The Global Herceptin Biosimilar Market Size was valued at USD 1,795 Million in 2021 and is predicted to be worth USD 11,287 Million by 2030, with a CAGR of 23.2% from 2022 to 2030.

The increasing number of individuals residing with gastric cancer and metastatic breast cancer is expected to stimulate demand opportunities for companies in the global Herceptin biosimilar market. Furthermore, increased research and development, as well as increased cancer therapy awareness, increase the Herceptin biosimilar market size. Additionally, rising healthcare costs and the existence of novel r&d investments provide an opportunity for Herceptin biosimilar market share. However, negative consequences caused by Herceptin biologic drugs, stringent regulations governing Herceptin biosimilar authorization, as well as the availability of alternative treatments available may limit the global Herceptin biosimilars market size.

Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein. In 2014, herceptin has lost the patent in Japan and Europe which has opened the gates for the development of the biosimilar to enter the market.  Whereas, the patent for the drug in U.S. will expire in 2019. The companies are continuously trying to introduce the new generic drugs to expand the global Herceptin biosimilars market value.

Global Herceptin Biosimilar Market Analysis

Market Drivers

• Rising prevalence and incidence of gastric and breast cancer
• Strong product pipeline from leading companies
• Increasing Advancement in the Healthcare Sector
• Endorsement of innovative Herceptin biosimilar prescription meds by key companies

Market Restraints

• Existence of Alternatives
• high costs for development
• Significant side effects associated with Herceptin 

Market Opportunities

• Strategic acquisitions and mergers by major influencers
• Increase in healthcare spending

Herceptin Biosimilar Market Report Coverage:

During last few years, there is a significant rise in the cancer patient pool. Increasing prevalence of the cancer and increasing demand for the targeted therapy have led to drive the Herceptin biosimilars market growth. Breast cancer is the most widely occurred cancer in the woman. According to the U.S. breast cancer Statistics, over 12.4% of the total American woman develops breast cancer in their lifetime. Changing lifestyle, increasing pollution and adoption of smoking by the people has fuelled the growth of the Herceptin biosimilars market value. As there are huge opportunity for the development of the cancer drug a number of companies are continuously investing a huge amount of capital in research and development. Increasing spending on research & development and increasing demand for the better drugs for the treatment has supported and created a huge opportunity in coming future.

On the other hand, availability of the alternative treatment and huge side effects of the drugs may slow the growth of the Herceptin biosimilars market size during the forecasted period.

Herceptin Biosimilar Market Segmentation           

The global herceptin biosimilar market segmentation based on the application, end-user and geographical region.

Market by Application

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lymphoma
• Others

According to the Herceptin biosimilar industry analysis, the breast cancer segment is predicted to lead the global market growth over the forecast. This growth is due to a rise in the prevalence and incidence of breast cancer in women. According to the World Health Organization, approximately 627,000 women will be diagnosed with breast cancer in 2019, increasing the demand for monoclonal antibodies & driving the expansion of this segment. As a result, Herceptin biosimilar market shares are influenced by these factors.

Market by End-User

• Hospital & Clinics
• Oncology Centers
• Others

In terms of end-user, hospital pharmacies are expected to hold the highest market share in 2021. This uptick is due to an increase in the number of individuals admitted to hospitals and medical centers for diagnosis, as well as hospital-provided health care infrastructural facilities such as ventilators and intensive care units (ICU).

Herceptin Biosimilar Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa